Injection of HLA-A24- or -A2-restricted GPC3 peptide (EYILSLEEL or FVGEFFTDV) Emulsified with Montanide ISA51 adjuvant. 3 mg intradermally injection, every 2 weeks, 6 times, and every 2 months, 4 t

2 trials

Sponsors

Division of Cancer Immunotherapy, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Section for Cancer Immunotherapy, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East

Conditions

Hepatocellular carcinoma(HCC)clear cell carcinoma of ovary

Phase 1

Phase II study of Glypican-3(GPC3) peptide vaccine as treatment for clear cell adenocarcinoma of ovary.

RecruitingJPRN-UMIN000003696

Section for Cancer Immunotherapy, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital Eastclear cell carcinoma of ovary

Start: 2010-06-01Target: 140Updated: 2026-06-29

Phase 2

A Phase II study of Glypican-3(GPC3) peptide vaccine as adjuvant treatment for Hepatocellular carcinoma(HCC) after Surgical resection or Radiofrequency ablation(RFA)

Active, not recruitingJPRN-UMIN000002614

Division of Cancer Immunotherapy, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital EastHepatocellular carcinoma(HCC)

Start: 2009-10-01Target: 40Updated: 2026-06-29

Related Papers

Cancer immunotherapy-targeted glypican-3 or neoantigens.

2018-02-1441 citations